Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Dynamic Prognosis Prediction for Patients on DAPT After Drug‐Eluting Stent Implantation: Model Development and Validation
10
Zitationen
23
Autoren
2024
Jahr
Abstract
BACKGROUND: The rapid evolution of artificial intelligence (AI) in conjunction with recent updates in dual antiplatelet therapy (DAPT) management guidelines emphasizes the necessity for innovative models to predict ischemic or bleeding events after drug-eluting stent implantation. Leveraging AI for dynamic prediction has the potential to revolutionize risk stratification and provide personalized decision support for DAPT management. METHODS AND RESULTS: We developed and validated a new AI-based pipeline using retrospective data of drug-eluting stent-treated patients, sourced from the Cerner Health Facts data set (n=98 236) and Optum's de-identified Clinformatics Data Mart Database (n=9978). The 36 months following drug-eluting stent implantation were designated as our primary forecasting interval, further segmented into 6 sequential prediction windows. We evaluated 5 distinct AI algorithms for their precision in predicting ischemic and bleeding risks. Model discriminative accuracy was assessed using the area under the receiver operating characteristic curve, among other metrics. The weighted light gradient boosting machine stood out as the preeminent model, thus earning its place as our AI-DAPT model. The AI-DAPT demonstrated peak accuracy in the 30 to 36 months window, charting an area under the receiver operating characteristic curve of 90% [95% CI, 88%-92%] for ischemia and 84% [95% CI, 82%-87%] for bleeding predictions. CONCLUSIONS: Our AI-DAPT excels in formulating iterative, refined dynamic predictions by assimilating ongoing updates from patients' clinical profiles, holding value as a novel smart clinical tool to facilitate optimal DAPT duration management with high accuracy and adaptability.
Ähnliche Arbeiten
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
2007 · 8.134 Zit.
2018 ESC/EACTS Guidelines on myocardial revascularization
2018 · 7.027 Zit.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 · 6.380 Zit.
Clinical End Points in Coronary Stent Trials
2007 · 5.403 Zit.
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2020 · 4.966 Zit.
Autoren
Institutionen
- Mayo Clinic in Florida(US)
- The University of Texas Health Science Center at Houston(US)
- Peng Cheng Laboratory(CN)
- The University of Texas Health Science Center(US)
- Louisiana State University Health Sciences Center New Orleans(US)
- University of Florida Health(US)
- University of Florida(US)
- Florida College(US)